{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:20:51Z","timestamp":1782915651069,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-10107-7","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:17:06Z","timestamp":1730107026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcome of combination of vancomycin and ceftaroline versus vancomycin monotherapy for treatment of methicillin resistant Staphylococcus aureus bloodstream infection"],"prefix":"10.1186","volume":"24","author":[{"given":"Rami","family":"Waked","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Coats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina F.","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Diekema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina E.","family":"Rokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Mercuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"2","key":"10107_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","volume":"25","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012;25(2):362\u201386.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10107_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/512627","volume":"28","author":"S Shurland","year":"2007","unstructured":"Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007;28(3):273\u20139.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"10107_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","volume":"38","author":"PA Moise","year":"2016","unstructured":"Moise PA, Culshaw DL, Wong-Beringer A, Bensman J, Lamp KC, Smith WJ, et al. Comparative effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia with Vancomycin MIC\u2009>\u20091\u00a0mg\/L: a multicenter evaluation. Clin Ther. 2016;38(1):16\u201330.","journal-title":"Clin Ther"},{"issue":"17","key":"10107_CR4","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/archinte.167.17.1861","volume":"167","author":"C Hawkins","year":"2007","unstructured":"Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med. 2007;167(17):1861\u20137.","journal-title":"Arch Intern Med"},{"issue":"4","key":"10107_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciz257","volume":"70","author":"E Minejima","year":"2020","unstructured":"Minejima E, Mai N, Bui N, Mert M, Mack WJ, She RC, et al. Defining the breakpoint duration of Staphylococcus aureus Bacteremia Predictive of poor outcomes. Clin Infect Dis. 2020;70(4):566\u201373.","journal-title":"Clin Infect Dis"},{"issue":"Supplement3","key":"10107_CR6","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1086\/519470","volume":"45","author":"MH Kollef","year":"2007","unstructured":"Kollef MH. Limitations of Vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis. 2007;45(Supplement3):S191\u20135.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10107_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1086\/520655","volume":"45","author":"HW Boucher","year":"2007","unstructured":"Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007;45(5):601\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10107_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40121-019-00277-2","volume":"9","author":"O Ahmad","year":"2020","unstructured":"Ahmad O, Crawford TN, Myint T. Comparing the outcomes of Ceftaroline Plus Vancomycin or Daptomycin Combination Therapy Versus Monotherapy in adults with complicated and prolonged Methicillin-Resistant Staphylococcus Aureus Bacteremia initially treated with Supplemental Ceftaroline. Infect Dis Ther. 2020;9(1):77\u201387.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10107_CR9","doi-asserted-by":"publisher","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","volume":"7","author":"EK McCreary","year":"2020","unstructured":"McCreary EK, Kullar R, Geriak M, Zasowski EJ, Rizvi K, Schulz LT, et al. Multicenter Cohort of patients with methicillin-resistant Staphylococcus aureus Bacteremia receiving Daptomycin Plus Ceftaroline compared with other MRSA treatments. Open Forum Infect Dis. 2020;7(1):ofz538.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10107_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","volume":"115","author":"DP Levine","year":"1991","unstructured":"Levine DP, Fromm BS, Reddy BR. Slow response to Vancomycin or Vancomycin plus Rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991;115(9):674\u201380.","journal-title":"Ann Intern Med"},{"key":"10107_CR11","unstructured":"Drug Approval Package. Teflaro (ceftaroline fosamil) NDA #200327 [Internet]. [cited 2022 Nov 14]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/200327orig1s000toc.cfm"},{"issue":"5","key":"10107_CR12","doi-asserted-by":"publisher","first-page":"e02483","DOI":"10.1128\/AAC.02483-18","volume":"63","author":"M Geriak","year":"2019","unstructured":"Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, et al. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2019;63(5):e02483\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"10107_CR13","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","volume":"132","author":"LM Baddour","year":"2015","unstructured":"Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435\u201386.","journal-title":"Circulation"},{"issue":"12","key":"10107_CR14","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1093\/cid\/ciab452","volume":"73","author":"W Rose","year":"2021","unstructured":"Rose W, Fantl M, Geriak M, Nizet V, Sakoulas G. Current paradigms of combination therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: does it work, which combination, and for which patients? Clin Infect Dis. 2021;73(12):2353\u201360.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10107_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/jac\/dku322","volume":"70","author":"KE Barber","year":"2015","unstructured":"Barber KE, Rybak MJ, Sakoulas G. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. J Antimicrob Chemother. 2015;70(1):311\u20133.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10107_CR16","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1128\/AAC.02354-12","volume":"57","author":"BJ Werth","year":"2013","unstructured":"Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, et al. Novel combinations of Vancomycin plus ceftaroline or oxacillin against methicillin-resistant Vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother. 2013;57(5):2376\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10107_CR17","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/phar.2034","volume":"37","author":"AM Casapao","year":"2017","unstructured":"Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ, REACH-ID Study Group. Early Administration of Adjuvant \u03b2-Lactam therapy in combination with vancomycin among patients with Methicillin-Resistant Staphylococcus aureus Bloodstream infection: a Retrospective, Multicenter Analysis. Pharmacotherapy. 2017;37(11):1347\u201356.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10107_CR18","doi-asserted-by":"publisher","first-page":"e01554","DOI":"10.1128\/AAC.01554-17","volume":"62","author":"J Truong","year":"2018","unstructured":"Truong J, Veillette JJ, Forland SC. Outcomes of Vancomycin plus a \u03b2-Lactam versus Vancomycin only for treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2018;62(2):e01554\u201317.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10107_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/cid\/civ808","volume":"62","author":"JS Davis","year":"2016","unstructured":"Davis JS, Sud A, O\u2019Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of Vancomycin and \u03b2-Lactam therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: a pilot Multicenter Randomized Controlled Trial. Clin Infect Dis. 2016;62(2):173\u201380.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10107_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jama.2020.0103","volume":"323","author":"SYC Tong","year":"2020","unstructured":"Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of Vancomycin or Daptomycin with vs without an antistaphylococcal \u03b2-Lactam on Mortality, Bacteremia, Relapse, or treatment failure in patients with MRSA Bacteremia: a Randomized Clinical Trial. JAMA. 2020;323(6):527\u201337.","journal-title":"JAMA"},{"issue":"1","key":"10107_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1128\/AAC.01204-13","volume":"58","author":"TJ Dilworth","year":"2014","unstructured":"Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, Mercier RC. \u03b2-Lactams enhance vancomycin activity against Methicillin-Resistant Staphylococcus aureus Bacteremia compared to vancomycin alone. Antimicrob Agents Chemother. 2014;58(1):102\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10107_CR22","doi-asserted-by":"publisher","first-page":"ofac491","DOI":"10.1093\/ofid\/ofac491","volume":"9","author":"MS Assadoon","year":"2022","unstructured":"Assadoon MS, Pearson JC, Kubiak DW, Kovacevic MP, Dionne BW. Evaluation of Vancomycin Accumulation in patients with obesity. Open Forum Infect Dis. 2022;9(10):ofac491.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10107_CR23","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.18549\/PharmPract.2018.03.1204","volume":"16","author":"RD Bowers","year":"2018","unstructured":"Bowers RD, Cooper AA, Wente CL, Wilson DT, Johnson SW, Drew RH. Evaluation of a Vancomycin dosing nomogram in obese patients weighing at least 100 kilograms. Pharm Pract (Granada). 2018;16(3):1204.","journal-title":"Pharm Pract (Granada)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10107-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10107-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10107-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:15:26Z","timestamp":1730294126000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10107-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10107"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10107-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the Declaration of Helsinki, ethics approval for the study was granted by the MaineHealth Institutional Review Board (IRB), reference number 2011880-1, which reviewed the study and determined that it met the criteria for exemption from full IRB review. The requirement for informed consent was also waived by the MaineHealth IRB, in accordance with U.S. federal regulations governing research on human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"1212"}}